Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Inhibition of SHP2 ameliorates psoriasis by decreasing TLR7 endosome localization

View ORCID ProfileYuyu Zhu, Fenli Shao, Wei Yan, Qiang Xu, View ORCID ProfileYang Sun
doi: https://doi.org/10.1101/2020.09.28.20202861
Yuyu Zhu
1 Nanjing University School of Life Sciences;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yuyu Zhu
  • For correspondence: dz1630014@smail.nju.edu.cn
Fenli Shao
2 School of Life Sciences, Nanjing University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shaofenli90@163.com
Wei Yan
3 West China Hospital, Sichuan University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yanweihappyhappy@163.com
Qiang Xu
2 School of Life Sciences, Nanjing University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: qiangxu@nju.edu.cn
Yang Sun
1 Nanjing University School of Life Sciences;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yang Sun
  • For correspondence: yangsun@nju.edu.cn
  • Abstract
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Psoriasis is a complex chronic inflammatory skin disease with unclear molecular mechanisms. Here, we identify Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) as a novel accelerator of psoriasis development. Both genetic ablation of SHP2 in macrophages and pharmacological inhibition of SHP2 prevents the development of psoriasis-like skin inflammation in an imiquimod-induced murine model of psoriasis. Mechanistically, SHP2 promotes the trafficking of Toll-like receptor 7 (TLR7) from Golgi to endosome through its interaction with and dephosphorylation of TLR7 at Tyr1024, which promotes the ubiquitination of TLR7 and psoriasis-like skin inflammation. Importantly, SHP2 allosteric inhibitor SHP099 reduces the expression of pro-inflammatory cytokines in peripheral blood mononuclear cells from human patients with psoriasis. Collectively, our findings identify SHP2 as a novel regulator of psoriasis and suggest that SHP2 inhibition may be a promising therapeutic approach for psoriatic patients.

Competing Interest Statement

Y.S. and Q.X. have a patent pending on use of SHP2 inhibitors in psoriasis (202010109716.0). The other authors declare no conflict of interest.

Funding Statement

This work was supported by National Natural Science Foundation of China (Nos. 81872877, 81730100, 91853109, 81673436, 81803142), and Mountain-Climbing Talents Project of Nanjing University.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Animal welfare and experimental procedures were approved by the Institutional Animal Care and Use Committee at Nanjing University. All human studies were approved by the Ethics Institutional Review Board of West China Hospital, Sichuan University.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The RNA-seq data have been deposited to the Gene Expression Omnibus with accession no. GSE147535. All other data needed to evaluate the conclusions in this manuscript are present in the paper.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 30, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of SHP2 ameliorates psoriasis by decreasing TLR7 endosome localization
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Inhibition of SHP2 ameliorates psoriasis by decreasing TLR7 endosome localization
Yuyu Zhu, Fenli Shao, Wei Yan, Qiang Xu, Yang Sun
medRxiv 2020.09.28.20202861; doi: https://doi.org/10.1101/2020.09.28.20202861
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Inhibition of SHP2 ameliorates psoriasis by decreasing TLR7 endosome localization
Yuyu Zhu, Fenli Shao, Wei Yan, Qiang Xu, Yang Sun
medRxiv 2020.09.28.20202861; doi: https://doi.org/10.1101/2020.09.28.20202861

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Dermatology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (412)
  • Dentistry and Oral Medicine (69)
  • Dermatology (47)
  • Emergency Medicine (142)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4843)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (674)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (626)
  • Health Policy (318)
  • Health Systems and Quality Improvement (203)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5326)
  • Intensive Care and Critical Care Medicine (328)
  • Medical Education (93)
  • Medical Ethics (25)
  • Nephrology (75)
  • Neurology (685)
  • Nursing (42)
  • Nutrition (114)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (205)
  • Oncology (439)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (778)
  • Public and Global Health (1810)
  • Radiology and Imaging (323)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)